Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial

por Gray, H. J., Benigno, B., Berek, J., Chang, J., Mason, J., Mileshkin, L., Mitchell, P., Moradi, M., Recio, F. O., Michener, C. M., Secord, A. Alvarez, Tchabo, N E., Chan, J. K., Young, J., Kohrt, H., Gargosky, S. E., Goh, J. C.
Publicado 2016